ALVAC-AIDSVAX Vaccine: Risk of Infection Reduced by 31%

  • Thread starter Borek
  • Start date
  • Tags
    Vaccine
In summary, a recent trial showed a 31% lower risk of infection for those who received the vaccine compared to those who received dummy shots. However, there are questions about the statistical significance of this difference and the confidence level that the vaccine actually provided immunity. After 20 years of not using statistics, it can be difficult to calculate, but it can be done using a Bernoulli trial and a Binomial distribution. Both the unequal variances t-test and the equal variance t-test show a high degree of statistical significance in rejecting the null hypothesis that the two groups were identical.
  • #1
Borek
Mentor
28,959
4,264
It hit the news in a last few days, you have probably heard about it. That's what I have found about the trial:

New infections occurred in 51 of the 8,197 given vaccine and in 74 of the 8,198 who received dummy shots. That worked out to a 31 percent lower risk of infection for the vaccine group.

And it makes me wonder - what is statistical significance of this diference? What is a confidence level that those that were given vaccine were in fact more immune? Or in other words - what is a confidence level that probability of contracting AIDS was lower in those that received vaccine? (Sure, we have to assume both group were otherwise identical).

In theory I should know how to calculate it, but after 20 years of lying somewhere in the dark corner my statistics is so rusty I prefer not to touch it, as it may fall apart
 
Physics news on Phys.org
  • #2
There are two groups: control vs. experiment.

If a group consists of N total individuals, n of whom were infected, then each individual within that group can be modeled as a Bernoulli trial with mean p = n/N and variance = p(1-p). A Bernoulli trial is an individual "experiment" with probability p of getting infected.

N trials are distributed Binomial with mean = Np = n and variance = Np(1-p) for the group as a whole.

Control group (m = 74, M = 8198):
...For an individual:
...Bernoulli probability: p = m/M = 0.00902659
...For the group:
...Binomial mean: m = 74
...Binomial variance: u = Mp(1-p) = 73.332.
Experiment group (n = 51, N = 8197)
...For an individual:
...Bernoulli probability: q = n/N = 0.00622179
...For the group:
...Binomial mean: n = 51
...Binomial variance: v = Nq(1-q) = 50.6827.

Unequal variances t-test:
...s = Sqrt[(Nu+Mv)/(MN)] = 0.122997
...t = (m - n)/s = 186.997
...d.f. = (u/M + v/N)^2 / ((u/M)^2/(M - 1) + (v/N)^2/(N - 1)) = 15,864.5
...The null hypothesis "true m = true n" can be rejected at a very high degree of statistical significance.

Equal variance t-test:
...S = Sqrt[((M-1)u+(N-1)v)/(M+N-2)] = 7.8745
...s = S Sqrt[1/M + 1/N] = 0.122998
...t = (m - n)/s = 186.995
...d.f. = M + N - 2 = 16,393
...Again, the null hypothesis "true m = true n" can be rejected at a very high degree of statistical significance.
 
Last edited:
  • #3
Many thanks.
 

Related to ALVAC-AIDSVAX Vaccine: Risk of Infection Reduced by 31%

1. What is the ALVAC-AIDSVAX vaccine?

The ALVAC-AIDSVAX vaccine is an experimental vaccine that is being developed to prevent HIV infection. It is a combination of two different vaccines: ALVAC, which is a weakened form of a virus that causes bird flu, and AIDSVAX, which is a protein that is found on the surface of HIV.

2. How does the ALVAC-AIDSVAX vaccine work?

The ALVAC-AIDSVAX vaccine works by stimulating the body's immune system to produce antibodies and immune cells that can specifically recognize and target the HIV virus. The ALVAC component of the vaccine acts as a vector, delivering genetic material from HIV to the body's cells. This triggers an immune response, and the AIDSVAX component of the vaccine helps to strengthen and focus this response on the specific protein found on the surface of the HIV virus.

3. What are the results of the study on the ALVAC-AIDSVAX vaccine?

The study on the ALVAC-AIDSVAX vaccine showed that it reduced the risk of HIV infection by 31%. This means that out of 100 people who were given the vaccine, 31 were protected from HIV infection compared to those who did not receive the vaccine. It is important to note that this is not a 100% effective vaccine, but it is a significant step towards finding an effective HIV vaccine.

4. What are the potential risks of the ALVAC-AIDSVAX vaccine?

Like any vaccine, the ALVAC-AIDSVAX vaccine may have potential risks and side effects. Some participants in the study experienced mild side effects such as soreness at the injection site, headache, and muscle aches. However, the vaccine has been shown to be generally safe and well-tolerated in clinical trials so far.

5. When will the ALVAC-AIDSVAX vaccine be available for public use?

The ALVAC-AIDSVAX vaccine is still in the experimental stage and is not currently available for public use. More research and clinical trials are needed to ensure its safety and effectiveness before it can be approved by regulatory agencies and made available to the public.

Similar threads

  • Biology and Medical
2
Replies
42
Views
4K
  • Biology and Medical
3
Replies
100
Views
6K
Replies
20
Views
1K
  • Biology and Medical
Replies
2
Views
1K
Replies
56
Views
5K
  • General Discussion
6
Replies
201
Views
18K
Replies
26
Views
3K
  • Biology and Medical
15
Replies
516
Views
27K
  • Biology and Medical
9
Replies
287
Views
19K
  • Biology and Medical
Replies
12
Views
2K
Back
Top